AstraZeneca (AZN) Earns Coverage Optimism Rating of 0.19
Media coverage about AstraZeneca (NYSE:AZN) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AstraZeneca earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.0022697029149 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
AstraZeneca (AZN) traded up $0.15 on Thursday, reaching $33.57. The company’s stock had a trading volume of 4,973,300 shares, compared to its average volume of 4,664,882. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. The stock has a market cap of $84,618.16, a PE ratio of 7.98, a price-to-earnings-growth ratio of 3.04 and a beta of 0.72. AstraZeneca has a 52 week low of $26.51 and a 52 week high of $35.60.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.32 EPS. equities research analysts predict that AstraZeneca will post 1.87 EPS for the current year.
Several brokerages recently weighed in on AZN. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the company a “buy” rating in a research note on Wednesday, November 15th. Leerink Swann boosted their target price on shares of AstraZeneca from $31.00 to $34.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Citigroup raised shares of AstraZeneca to a “buy” rating in a research note on Wednesday, October 18th. Cowen reissued a “hold” rating and issued a $37.00 target price on shares of AstraZeneca in a research note on Tuesday, October 17th. Finally, Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $34.20.
WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/12/14/astrazeneca-azn-earns-coverage-optimism-rating-of-0-19.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.